BIXT · Bioxytran, Inc
$0.02
0.00 (-3.96%)
At close · Jul 30
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue operations.”View the 10-Q filed May 15, 2026
Market Cap
$2.59M
Shares
114.20M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.02
Open$0.02
Day$0.02–0.02
52W$0.02–0.10
Avg vol 30d35K
Short int15K · 0.0% float · 1.0d
Short vol71%
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−54%
below
Price vs 50-day avg
−22%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
−58%
trailing
YTD return
−71%
this year
Relative strength
−67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -2.0% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Squeeze score
25
low risk · 0–100
Fundamentals
Revenue growth
−22%
Y/Y
Gross margin
46%
contracting
EPS growth
0%
Y/Y
Balance sheet
$11.1K
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−54%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -2.0% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $0
vs 200-day avg -54%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIXT
this stock
Bioxytran, Inc
|
$2.59M | -71.2% | -22.5% | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$465.49B | +6.0% | +22179.2% | 947.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.26B | +6.3% | +46.2% | 28.6 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.02B | -4.2% | +20.8% | 18.3 | 3.4% |
|
ARGX
Argenx SE
|
$53.42B | +3.8% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIXT | -8.4% | -24.3% | -57.7% | -16.2% | -71.2% |
| SPY | +0.5% | -0.6% | +9.5% | -0.7% | +8.8% |
| vs SPY | -8.9% | -23.8% | -67.1% | -15.5% | -80.0% |